Please login to the form below

Not currently logged in
Email:
Password:

Antibody testing

This page shows the latest Antibody testing news and features for those working in and with pharma, biotech and healthcare.

Eli Lilly reports first results for COVID-19 targeting antibody

Eli Lilly reports first results for COVID-19 targeting antibody

Also, in exploratory analyses, Lilly added that LY-CoV555 seemed to improve COVID-19 symptoms at a faster rate compared to those who did not receive the antibody treatment. ... The BLAZE-1 study is also still ongoing, with Lilly aiming to enrol a total

Latest news

  • Britain ramps up COVID-19 testing to track spread of infections Britain ramps up COVID-19 testing to track spread of infections

    Regular testing will increase from 28, 000 people per fortnight to 150, 000 by October. ... restrictions. The survey, co-led by the ONS and The University of Oxford, will use routine swabbing and antibody testing to provide key insights into the rate of

  • Speed kills Speed kills

    From testing to reopening to vetting scientific articles, we have lost track of time. ... Diagnostic and antibody testing has not been excluded from this obsession with velocity either.

  • Delivering safe and effective clinical trials during the COVID-19 pandemic Delivering safe and effective clinical trials during the COVID-19 pandemic

    Secondly, we used antibody testing to establish whether there had already been mild infections; none were detected. ... This ensures that we do not miss asymptomatic infections. We have implemented accurate antibody testing (RAPG-COV-019) that indicates

  • Almirall eyes $62m takeover of multicytokine specialist Bioniz Almirall eyes $62m takeover of multicytokine specialist Bioniz

    BNZ-1 a selective and simultaneous inhibitor of cytokines IL-2, IL-9 and IL-15 which is in early-stage testing for CTCL and also has potential for alopecia areata, ... The option deal comes amid an expansionist phase for Almirall, which exercised an

  • Medimmune-born Viela files $150m IPO, eyes first product launch Medimmune-born Viela files $150m IPO, eyes first product launch

    Inebilizumab is an anti-CD19 antibody developed initially to treat neuromyelitis optica spectrum disorder (NMOSD), also known as Devic’s disease, that attacks the optic nerves and spinal cord and can ... It will also help push anti-ILT7 antibody

More from news
Approximately 0 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    AbbVie is testing its anti-tau antibody ABBV-8E12 in a phase 2 trial, while Biogen has links to two midphase tau programmes. ... The big biotech is testing its own BIIB092 in early Alzheimer’s patients and has an option to develop an Ionis

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics